SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Jun 30, 2026 → Jun 30, 2028
See other at-risk trials from CSPC Megalith Biopharmaceutical Co.,Ltd.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jun 30, 2026 to Jun 30, 2028 Show 6 more changesShow less
    • Enrollment increased: 70 → 110 participants
    • Study completion pushed from Dec 31, 2027 to Dec 31, 2028
    • Interventions modified
    • Trial arms changed: 2 → 3
    • Start date: Dec 18, 2025 to Dec 12, 2025
    • Eligibility criteria expanded, about 64 words
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 1, 2025 to Dec 18, 2025
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This study is an open-label, multi-center, phase II study to evaluate the efficacy and safety of SYS6010 combined with immunotherapy in the recurrent or metastatic head and neck squamous cell carcinoma.
Trial Details
NCT Number NCT07254585
Lead Sponsor CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions
(from sponsor)		 Head and Neck Squamous Cell Carcinoma
Related terms Squamous Cell Carcinoma of Head and Neck
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov